[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338605-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338605-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-therapeutic-potential-of-rna-m6a-in-lung-cancer","The therapeutic potential of RNA m(6)A in lung cancer","","Lung cancer is a highly malignant, metastatic disease with rising global incidence and mortality, and a 5-year overall survival rate below 20%. Limited understanding of its pathogenesis and lack of curative options for mid- to advanced stages contribute to ongoing therapeutic failure. RNA m(6)A, a prevalent N6-methylation mark of adenosine essential for cellular development and homeostasis, becomes deregulated in lung cancer, promoting proliferation, stemness, invasion, EMT, metastasis, and therapy resistance. Targeting RNA m(6)A dysfunction can suppress growth and viability, trigger cell death, and reverse treatment insensitivity, supporting novel lung cancer strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-therapeutic-potential-of-rna-m6a-in-lung-cancer/338605/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-therapeutic-potential-of-rna-m6a-in-lung-cancer/338605.png","ImageObject",300,407,{"name":42,"@type":43},"Theodora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is RNA m(6)A relevant to lung cancer therapy?","Question",{"text":63,"@type":64},"RNA m(6)A is deregulated in lung cancer and can drive malignant traits and therapeutic resistance. Eliminating RNA m(6)A dysfunction can produce anti-cancer effects and reverse treatment insensitivity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What cancer behaviors does dysregulated RNA m(6)A promote in lung cancer?",{"text":68,"@type":64},"RNA m(6)A dysregulation promotes proliferation, stemness, invasion, epithelial-mesenchymal transition (EMT), metastasis, and therapeutic resistance.",{"name":70,"@type":61,"acceptedAnswer":71},"How is lung cancer generally classified in the document?",{"text":72,"@type":64},"Lung cancer is divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC comprising about 85% of cases and including subtypes such as LUAD, LSCC, and LLCC.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338605,1790878092,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":97,"preview_urls":146},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Yu etal. Cell Communication and Signaling (2024) 22:617  \n[https://doi.org/10.1186/s12964-024-01980-5](https://doi.org/10.1186/s12964-024-01980-5)  \nCell Communication and Signaling  \n REVIEW Open Access  \nThe therapeutic potential of RNA m(6)Ain lung cancer  \nJingran Yu1†, Wei Sun2†, Xiangxuan Zhao3,4* andYingying Chen1*  \nAbstract  \nLung cancer (LC) is a highly malignant and metastatic form of cancer. The global incidence of and mortality from LCis steadily increasing; the mean 5-year overall survival (OS) rate for LC is less than 20% . This frustrating situation maybe attributed to the fact that the pathogenesis of LC remains poorly understood and there is still no cure for mid to advanced LC. Methylation at the N6-position of adenosine (N6 mA) of RNA (m(6)A) is widely present in human tissues and organs, and has been found to be necessary for cell development and maintenance of homeostasis. However, numerous basic and clinical studies have demonstrated that RNA m(6)A is deregulated in many human malignancies including LC. This can drive LC malignant characteristics such as proliferation, stemness, invasion, epithelial-mesenchymal transition (EMT), metastasis, and therapeutic resistance. Intriguingly, an increasing number of studies have also shown that eliminating RNA m(6)A dysfunction can exert significant anti-cancer effects on LC such as suppression of cell proliferation and viability, induction of cell death, and reversal of treatment insensitivity. The current review comprehensively discusses the therapeutic potential of RNA m(6)A and its underlying molecular mechanisms in LC, providing useful information for the development of novel LC treatment strategies.  \nKeywords Lung cancer, M(6)A, Epigenetics, Target therapy, Tumorigenesis  \nIntroduction  \nLung cancer (LC), originating from the bronchial mucosal epithelium, is one of the most common malignant cancer types in humans. Among all cancer types, LC ranks second and first in terms of morbidity and mortality, respectively [1]. LC can be mainly divided  \n†Jingran Yu and Wei Sun contributed equally to this work.  \n*Correspondence:  \nXiangxuan Zhao [xiangxuanzhao@163.com](xiangxuanzhao@163.com)[ ](xiangxuanzhao@163.com)Yingying Chen [2002chenyingying@163.com](2002chenyingying@163.com)  \n1 Department of Pulmonary and Critical Care Medicine, Shengjing Hospital of China Medical University, No. 39 Huaxiang Road, Shenyang, Liaoning 110022, China  \n2 Department of Radiology, Shengjing Hospital of China Medical University, No. 36 Sanhao Street, Shenyang 110004, China  \n3 Center for Innovative Engineering Technology in Traditional Chinese Medicine, Liaoning University of Traditional Chinese Medicine, No.79 Chongshandong Road, Shenyang 110847, China  \n4 Health Sciences Institute, China Medical University, Puhe Road, Shenyang North New Area, Shenyang 110022, China  \ninto two subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The former accounts for approximately 85% of the total number of LC cases and can be further divided pathologically into adenocarcinoma (LUAD), squamous cell carcinoma (LSCC), and large cell carcinoma (LLCC). Among these, LUADis the most common subtype, accounting for approximately 35% to 40% of all NSCLC [2]. LC is a common disease caused by multiple factors, however, its specific pathogenesis remains unclear. Currently, most tumor biologists believe that LC formation can be attributed to a combination of genetic and environmental factors [3]. A susceptibility locus identified in chromosome 6q23-25 of some family groups of LC patients suggests genetic inheritance may be a factor [4]. The three main susceptibility sites for LC caused by gene mutations or variations are located on chromosomes 15q25, 5p15, and 6p21 [5–7]. The most common gene mutations in LC tissues mainly include epidermal growth factor receptor (EGFR), Kirsten rat sarcoma (K-Ras), echinoderm  \n© The Author(s) 2024. Open Access This article is licensed under a Creat","cbCaivQkP8UVeEqD","https://ap.wps.com/l/cbCaivQkP8UVeEqD","pdf",2115492,42,"English","# Introduction\n## Lung cancer subtypes and epidemiology\n## Genetic and environmental contributors\n## Susceptibility loci and common driver mutations","[{\"question\":\"Why is RNA m(6)A relevant to lung cancer therapy?\",\"answer\":\"RNA m(6)A is deregulated in lung cancer and can drive malignant traits and therapeutic resistance. Eliminating RNA m(6)A dysfunction can produce anti-cancer effects and reverse treatment insensitivity.\"},{\"question\":\"What cancer behaviors does dysregulated RNA m(6)A promote in lung cancer?\",\"answer\":\"RNA m(6)A dysregulation promotes proliferation, stemness, invasion, epithelial-mesenchymal transition (EMT), metastasis, and therapeutic resistance.\"},{\"question\":\"How is lung cancer generally classified in the document?\",\"answer\":\"Lung cancer is divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC comprising about 85% of cases and including subtypes such as LUAD, LSCC, and LLCC.\"}]","The therapeutic potential of RNA m(6)A in lung cancer | PDF",1790024452,106,[147,151,155,159,163],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87c6a36c9f3669acdb15946d78908349.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cebb2f87a37b49e5679c49b179d8fd05.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e47209db6e3d8e0fc457ef50ecab6432.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/318a5befc9142d12606a38fa5beb0a3b.webp",980,1301,{"page_no":97,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01f77e8e9115bdfc9963ce733c6485f8.webp",979,1300]